EyePoint Pharmaceuticals, Inc.
EYPT
$11.21
$0.131.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -175.38M | -146.78M | -130.87M | -103.57M | -86.82M |
| Total Depreciation and Amortization | 1.91M | 1.73M | 1.54M | 1.19M | 892.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.42M | 24.84M | 30.88M | 27.85M | 25.87M |
| Change in Net Operating Assets | -40.54M | -27.97M | -27.77M | -38.95M | -29.60M |
| Cash from Operations | -190.59M | -148.18M | -126.23M | -113.49M | -89.66M |
| Capital Expenditure | -3.45M | -3.13M | -4.05M | -4.55M | -4.70M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 11.55M | -197.50M | -215.30M | -165.99M | -183.76M |
| Cash from Investing | 8.10M | -200.64M | -219.36M | -170.54M | -188.46M |
| Total Debt Issued | -- | -- | -- | 0.00 | 0.00 |
| Total Debt Repaid | -156.00K | -140.00K | -105.00K | -73.00K | 0.00 |
| Issuance of Common Stock | 164.99M | 165.34M | 169.31M | 235.75M | 234.48M |
| Repurchase of Common Stock | -1.32M | -1.37M | -4.51M | -4.51M | -4.43M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -656.00K | -874.00K | -672.00K | -343.00K | -758.00K |
| Cash from Financing | 162.87M | 162.96M | 164.02M | 230.82M | 229.29M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -19.63M | -185.86M | -181.56M | -53.21M | -48.83M |